Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.41 |
| ▸ | DHODH | Q02127 | 2/20 | 0.34 |
| ▸ | PDE5A | O76074 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | XBP1 | P17861 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29909353 | 0.90 | ABCG2 (0.37) | ABCG2DHODHPDE5ANPC1POLB | |
| SCHEMBL29909741 | 0.89 | NPC1 (0.43) | ABCG2DHODHPDE5ANPC1POLB | |
| SCHEMBL29909705 | 0.88 | ABCG2 (0.37) | ABCG2DHODHPDE5ANPC1POLB | |
| SCHEMBL29909687 | 0.88 | ABCG2 (0.37) | ABCG2DHODHPDE5AATM | |
| SCHEMBL29909758 | 0.88 | ABCG2 (0.37) | ABCG2DHODHPDE5A | |
| SCHEMBL29909361 | 0.88 | HSD17B1 (0.39) | ABCG2PDE5AATM | |
| SCHEMBL29909750 | 0.87 | ABCG2 (0.36) | ABCG2DHODHPDE5ANPC1POLB | |
| SCHEMBL29909849 | 0.86 | SCN9A (0.37) | ABCG2ATMALDH1A1 | |
| SCHEMBL29909542 | 0.85 | ABCG2 (0.34) | ABCG2PDE5A | |
| SCHEMBL30961080 | 0.85 | CNR2 (0.38) | ABCG2ATMKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12054490-B2 | Diacylglycerol kinase modulating compounds | GILEAD SCIENCES, INC. (US) | 2024-08-06 | — | — | US | disclosed |
| CN-118324767-A | Diacylglycerol kinase modulating compounds | 卡尔那生物科学株式会社 | 2024-07-12 | — | — | CN | disclosed |
| EP-4081305-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | Carna Biosciences, Inc. (JP) | 2022-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12054490-B2 | Diacylglycerol kinase modulating compounds | DGKG, DGKB, DGKK | ABCG2 4216/4885DHODH 1705/4885PDE5A 1924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.